Floatz logo

cd19/cd22 car-t

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The First Affiliated Hospital of Soochow UniversityCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Relapsed or Refractory B-cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 2B
Pemigatinib
University of Utah
Phase 2CCC

Same molecule, other indications

cd19/cd22 car-t is also rated in:

B-ALLDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →